-
公开(公告)号：KR1020030027422A
公开(公告)日：2003-04-07
申请号：KR1020010060657
申请日：2001-09-28
Applicant: 한국화학연구원
IPC: A61K47/48
CPC classification number: A61K47/6949 , A61K31/546
Abstract: PURPOSE: Provided is a pharmaceutical composition obtained by including cefuroxime axetil with sodium alginate and then formulating into dry syrups to suppress a bitter taste of cefuroxime axetil. The composition is harmless to the human body and improves compliance by a patient. CONSTITUTION: The pharmaceutical composition is prepared by mixing 1 part by weight of cefuroxime axetil, 2 to 10 parts by weight of sodium alginate, 1 to 3 parts by weight of calcium chloride as a cross-linking agent, 1 to 2 parts by weight of stearic acid, 15 to 25 parts by weight of a pharmaceutically acceptable disintegrating agent and 5 to 15 parts by weight of pharmaceutically acceptable sugars.
Abstract translation: 目的：提供通过将头孢呋辛酯与藻酸钠包埋，然后配制成干糖浆以抑制头孢呋辛酯的苦味而得到的药物组合物。 组合物对人体无害，并改善患者的依从性。 构成：通过将1重量份头孢呋辛酯，2〜10重量份藻酸钠，1〜3重量份作为交联剂的氯化钙，1〜2重量份的 硬脂酸，15至25重量份的药学上可接受的崩解剂和5至15重量份的药学上可接受的糖。
-
公开(公告)号：KR1020020024714A
公开(公告)日：2002-04-01
申请号：KR1020000056496
申请日：2000-09-26
Applicant: 한국화학연구원
IPC: A61K9/24
CPC classification number: A61K9/1676 , A61K31/407
Abstract: PURPOSE: Provided is a controlled release pellet containing ketorolac tromethamine, thereby reducing dosage and consequently increasing drug stability and decreasing side effects. CONSTITUTION: The controlled release pellet containing ketorolac tromethamine characteristically consists of a crystalline core(1) having a size of 300-1000 micrometer, an inner layer(2) including ketorolac tromethamine, and a controlled release type of outer layer(3) containing Eudragit as an essential ingredient and optionally a water-soluble polymer.
Abstract translation: 目的：提供含有酮咯酸氨丁三醇的控释丸，从而减少剂量，从而增加药物稳定性和减少副作用。 构成：含有酮咯酸氨丁三醇的控制释放颗粒特征性地由尺寸为300-1000微米的结晶核心（1），包含酮咯酸氨丁三醇的内层（2）和含有Eudragit的控释型外层（3）组成 作为必需成分和任选的水溶性聚合物。
-
公开(公告)号：KR1020000046614A
公开(公告)日：2000-07-25
申请号：KR1019980063311
申请日：1998-12-31
Applicant: 한국화학연구원
IPC: A61K47/30
Abstract: PURPOSE: A drug transmission carrier composition useful in preparing a gel matrix, microspheres, or fibers with excellent drug penetration and strength, and a preparation method thereof are provided. CONSTITUTION: A drug delivery carrier composition consists of a carrier compound such as polyvinyl alcohol and subsidiary dissolving agents such as diethylene glycolmonoethyl ether, ethylene glycol monoethyl ether and ethylene glycol monomethyl ether. Soluble polymer such as polyalkyl glycol compounds, polyacrylic acid, polyvinyl pyrolidone, sodium alginate, and gelatine may be added to improve the strength of the composition,. The method for producing carrier composition comprises the steps of: dissolving polyvinyl in distilled water; and adding subsidiary dissolving agents to the mixed solution.
Abstract translation: 目的：提供一种可用于制备具有优异的药物渗透性和强度的凝胶基质，微球或纤维的药物传播载体组合物及其制备方法。 构成：药物递送载体组合物由聚乙烯醇等载体化合物和二乙二醇单乙醚，乙二醇单乙醚，乙二醇单甲醚等辅助溶解剂组成。 可以加入可溶性聚合物如聚烷基二醇化合物，聚丙烯酸，聚乙烯吡咯烷酮，藻酸钠和明胶，以提高组合物的强度。 制备载体组合物的方法包括以下步骤：将聚乙烯醇溶解在蒸馏水中; 并向混合溶液中加入辅助溶解剂。
-
-
公开(公告)号：KR1019990065619A
公开(公告)日：1999-08-05
申请号：KR1019980001003
申请日：1998-01-15
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: 에스트라디올과 같은 호르몬제의 경피투과법으로서, 호르몬제, 피부확장제 및 점착제로 이루어진 용액에 혼합용매에 용해시킨 수용성 고분자를 혼합한 후 용매를 증발시켜 제조된 매트릭스형 패치 조성물은 셀룰로오스 계통의 수용성 고분자를 사용함으로써 호르몬제의 투과율을 높일 뿐만 아니라 안정성을 높여 안정성 실험시 호르몬제의 결정화가 일어나지 않는다.
-
Patent Agency Ranking
-
公开(公告)号：KR100155444B1
公开(公告)日：1998-11-16
申请号：KR1019950021742
申请日：1995-07-22
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: 생체적합성, 알레르기 비유발성의 고분자 물질을 극성 유기 용매에 용해시키고, 셀룰로우스 계통 또는 글라이콜 계통의 폴리 알콜 혹은 알콜화합물, 접착제 및 의약을 알칸올과 극성 유기 용매의 혼합 용매에 용해시킨 다음, 상기의 두 액상 물질을 균질화기로 완전히 균등한 혼합물이 되도록 혼합한 후, 상기 혼합 용액을 유리판 위에 일정한 두께로 도포한 다음, 건조하여 제조된 소수성 고분자의 매트릭스를 이용하여 얻어지는 피부 약물 전달 체계는 별도의 약물 저장 수단 및 접착제 코팅이 필요 없으며, 약물 방출 조절이 우수한 피부 약물 전달 체계이다.
-
-
-
-
-
-
-
Search Results
127
records
(took 0.023 seconds)
